These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29059492)

  • 41. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
    Miller TW; Traphagen NA; Li J; Lewis LD; Lopes B; Asthagiri A; Loomba J; De Jong J; Schiff D; Patel SH; Purow BW; Fadul CE
    J Neurooncol; 2019 Sep; 144(3):563-572. PubMed ID: 31399936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
    Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
    Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
    Tien AC; Li J; Bao X; Derogatis A; Kim S; Mehta S; Sanai N
    Clin Cancer Res; 2019 Oct; 25(19):5777-5786. PubMed ID: 31285369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
    Nishikawa T; Matsumoto K; Tamura K; Yoshida H; Imai Y; Miyasaka A; Onoe T; Yamaguchi S; Shimizu C; Yonemori K; Shimoi T; Yunokawa M; Xiong H; Nuthalapati S; Hashiba H; Kiriyama T; Leahy T; Komarnitsky P; Fujiwara K
    Cancer Sci; 2017 Sep; 108(9):1834-1842. PubMed ID: 28665051
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
    Molife LR; Dean EJ; Blanco-Codesido M; Krebs MG; Brunetto AT; Greystoke AP; Daniele G; Lee L; Kuznetsov G; Myint KT; Wood K; de Las Heras B; Ranson MR
    Clin Cancer Res; 2014 Dec; 20(24):6284-94. PubMed ID: 25278451
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
    Yardley DA; Hart L; Favret A; Blau S; Diab S; Richards D; Sparano J; Beck JT; Richards P; Ward P; Ramaswamy B; Tsai M; Blackwell K; Pluard T; Tolaney SM; Esteva FJ; Truica CI; Alemany C; Volas-Redd G; Shtivelband M; Purkayastha D; Dalal AA; Miller M; Hortobagyi GN
    Clin Breast Cancer; 2019 Aug; 19(4):268-277.e1. PubMed ID: 31160171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
    Patnaik A; Rosen LS; Tolaney SM; Tolcher AW; Goldman JW; Gandhi L; Papadopoulos KP; Beeram M; Rasco DW; Hilton JF; Nasir A; Beckmann RP; Schade AE; Fulford AD; Nguyen TS; Martinez R; Kulanthaivel P; Li LQ; Frenzel M; Cronier DM; Chan EM; Flaherty KT; Wen PY; Shapiro GI
    Cancer Discov; 2016 Jul; 6(7):740-53. PubMed ID: 27217383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
    McRee AJ; Sanoff HK; Carlson C; Ivanova A; O'Neil BH
    Invest New Drugs; 2015 Dec; 33(6):1225-31. PubMed ID: 26490655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors.
    Ando Y; Iwasa S; Takahashi S; Saka H; Kakizume T; Natsume K; Suenaga N; Quadt C; Yamada Y
    Cancer Sci; 2019 Mar; 110(3):1021-1031. PubMed ID: 30588709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
    Chen D; Sun X; Zhang X; Cao J
    Biomed Res Int; 2020; 2020():9525207. PubMed ID: 32626773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
    Saeki T; Takashima S; Terashima M; Satoh A; Toi M; Osaki A; Toge T; Ohno S; Nomura N; Fukuyama Y; Koizumi W; Taguchi T
    Int J Clin Oncol; 2005 Feb; 10(1):51-7. PubMed ID: 15729602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
    Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity.
    Ippolito E; Greco C; Silipigni S; Dell'Aquila E; Petrianni GM; Tonini G; Fiore M; D'Angelillo RM; Ramella S
    Breast; 2019 Aug; 46():70-74. PubMed ID: 31100573
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
    Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F
    Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.